Koroglu M, Karakaplan M, Gunduz E, Kesriklioglu B, Ergen E, Aslanturk O
Orphanet J Rare Dis. 2024; 19(1):53.
PMID: 38336741
PMC: 10858589.
DOI: 10.1186/s13023-024-03082-4.
Ribeiro R, Vasconcelos S, Lima P, Coelho E, Oliveira A, Gomes E
Brain Sci. 2023; 13(7).
PMID: 37508912
PMC: 10377253.
DOI: 10.3390/brainsci13070979.
Khan A, Tian S, Tariq M, Khan S, Safeer M, Ullah N
Mol Genet Genomics. 2022; 297(6):1601-1613.
PMID: 36002593
DOI: 10.1007/s00438-022-01945-8.
Koyama S, Sekijima Y, Ogura M, Hori M, Matsuki K, Miida T
J Atheroscler Thromb. 2021; 28(9):905-925.
PMID: 33967188
PMC: 8532057.
DOI: 10.5551/jat.RV17055.
Kisa P, Yildirim G, Ozturk Hismi B, Dorum S, Kusbeci O, Topak A
Metab Brain Dis. 2021; 36(6):1201-1211.
PMID: 33704661
DOI: 10.1007/s11011-021-00714-7.
Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis.
Zubarioglu T, Bilen I, Kiykim E, Dogan B, Enver E, Cansever M
Turk Pediatri Ars. 2019; 54(2):113-118.
PMID: 31384146
PMC: 6666357.
DOI: 10.14744/TurkPediatriArs.2019.23281.
Late-onset Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.
Sasamura A, Akazawa S, Haraguchi A, Horie I, Ando T, Abiru N
Intern Med. 2018; 57(11):1611-1616.
PMID: 29434128
PMC: 6028668.
DOI: 10.2169/internalmedicine.0120-17.
Bilateral Femoral Neck Fractures in Cerebrotendinous Xanthomatosis Treated by Hip Arthroplasties: The First Case Report and Literature Review.
Wejjakul W, Chatmaitri S, Wattanarojanaporn T, Pongkunakorn A, Ittiwut C, Shotelersuk V
J Orthop Case Rep. 2017; 7(5):54-58.
PMID: 29242796
PMC: 5728000.
DOI: 10.13107/jocr.2250-0685.894.
Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).
Salen G, Steiner R
J Inherit Metab Dis. 2017; 40(6):771-781.
PMID: 28980151
DOI: 10.1007/s10545-017-0093-8.
Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.
Nie S, Chen G, Cao X, Zhang Y
Orphanet J Rare Dis. 2014; 9:179.
PMID: 25424010
PMC: 4264335.
DOI: 10.1186/s13023-014-0179-4.
Psychiatric manifestations in cerebrotendinous xanthomatosis.
Fraidakis M
Transl Psychiatry. 2013; 3:e302.
PMID: 24002088
PMC: 3784765.
DOI: 10.1038/tp.2013.76.
Cerebrotendinous xanthomatosis: a rare disorder with a rare presentation.
Agrawal N, Garg S
BMJ Case Rep. 2012; 2012.
PMID: 23001091
PMC: 4543233.
DOI: 10.1136/bcr-2012-006202.
Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis.
Mignarri A, Rossi S, Ballerini M, Gallus G, Del Puppo M, Galluzzi P
J Neurol. 2010; 258(5):783-90.
PMID: 21104094
DOI: 10.1007/s00415-010-5829-4.
The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.
DuSell C, Nelson E, Wang X, Abdo J, Modder U, Umetani M
Endocrinology. 2010; 151(8):3675-85.
PMID: 20501668
PMC: 2940523.
DOI: 10.1210/en.2010-0080.
Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D.
Gupta R, Patrick K, Bell N
Metabolism. 2007; 56(9):1248-55.
PMID: 17697869
PMC: 2707179.
DOI: 10.1016/j.metabol.2007.04.023.
Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.
Dotti M, Rufa A, Federico A
J Inherit Metab Dis. 2002; 24(7):696-706.
PMID: 11804206
DOI: 10.1023/a:1012981019336.
